Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 1781087, 7 pages
https://doi.org/10.1155/2017/1781087
Research Article

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

1Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
2Department of Pathology, University Hospitals Leuven, Leuven, Belgium
3Department of Oncology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
4Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium

Correspondence should be addressed to Annelies Requilé; moc.liamg@eliuqerseilenna

Received 30 July 2017; Revised 29 October 2017; Accepted 6 November 2017; Published 28 December 2017

Academic Editor: U. Dirksen

Copyright © 2017 Annelies Requilé et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Miser, T. Kinsella, T. Triche et al., “Treatment of peripheral neuroepithelioma in children and young adults,” Journal of Clinical Oncology, vol. 5, no. 11, pp. 1752–1758, 1987. View at Publisher · View at Google Scholar
  2. C. D. Fletcher, P. Hogendoorn, F. Mertens, and J. Bridge, WHO Classification of Tumours of Soft Tissue and Bone, IARC Press, Lyon, France, 4th edition, 2013.
  3. M. A. Applebaum, J. Worch, K. K. Matthay et al., “Clinical features and outcomes in patients with extraskeletal Ewing sarcoma,” Cancer, vol. 117, no. 13, pp. 3027–3032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. K. N. Ganjoo and S. Patel, “The treatment outcome for adult patients with Ewing’s sarcoma,” Current Oncology Reports, vol. 15, no. 4, pp. 372–377, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Jaffe, D. Paed, D. Traggis, S. Salian, and J. R. Cassady, “Improved outlook for Ewing’s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy,” Cancer, vol. 38, no. 5, pp. 1925–1930, 1976. View at Publisher · View at Google Scholar
  6. M. E. Nesbit Jr., E. A. Gehan, E. O. Burgert Jr. et al., “Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study,” Journal of Clinical Oncology, vol. 8, no. 10, pp. 1664–1674, 1990. View at Publisher · View at Google Scholar
  7. E. O. Burgert Jr., M. E. Nesbit, L. A. Garnsey et al., “Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II,” Journal of Clinical Oncology, vol. 8, no. 9, pp. 1514–1524, 1990. View at Publisher · View at Google Scholar
  8. H. E. Grier, M. D. Krailo, N. J. Tarbell et al., “Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone,” New England Journal of Medicine, vol. 348, no. 8, pp. 694–701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Granowetter, R. Womer, M. Devidas et al., “Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study,” Journal of Clinical Oncology, vol. 27, no. 15, pp. 2536–2541, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Paulussen, A. W. Craft, I. Lewis et al., “Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment–cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients,” Journal of Clinical Oncology, vol. 26, no. 27, pp. 4385–4393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Gaspar, D. S. Hawkins, U. Dirksen et al., “Ewing sarcoma: current management and future approaches through collaboration,” Journal of Clinical Oncology, vol. 33, no. 27, pp. 3036–3046, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Paulussen, S. Ahrens, S. Burdach et al., “Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies,” Annals of Oncology, vol. 9, no. 3, pp. 275–281, 1998. View at Google Scholar
  13. H. E. Grier, “The Ewing family of tumors. Ewing’s sarcoma and primitive neuroectodermal tumors,” Pediatric Clinics of North America, vol. 44, no. 4, pp. 991–1004, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Obata, T. Ueda, A. Kawai et al., “Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study,” Cancer, vol. 109, no. 4, pp. 767–775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Bacci, A. Longhi, S. Ferrari, M. Mercuri, M. Versari, and F. Bertoni, “Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998,” Acta Oncologica, vol. 45, no. 4, pp. 469–475, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. E. H. Baldini, G. D. Demetri, C. D. Fletcher, J. Foran, K. C. Marcus, and S. Singer, “Adults with Ewing’s sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome,” Annals of Surgery, vol. 230, no. 1, pp. 79–86, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. S. J. Cotterill, S. Ahrens, M. Paulussen et al., “Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3108–3114, 2000. View at Publisher · View at Google Scholar
  18. C. Rodríguez-Galindo, T. Liu, M. J. Krasin et al., “Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies,” Cancer, vol. 110, no. 2, pp. 375–384, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Fizazi, N. Dohollou, J. Y. Blay et al., “Ewing’s family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients,” Journal of Clinical Oncology, vol. 16, no. 12, pp. 3736–3743, 1998. View at Publisher · View at Google Scholar
  20. H. W. Hense, S. Ahrens, M. Paulussen, M. Lehnert, and H. Jürgens, “Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies,” Annals of Oncology, vol. 10, no. 9, pp. 1073–1077, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. F. B. Askin, J. Rosai, R. K. Sibley, L. P. Dehner, and W. H. McAlister, “Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis,” Cancer, vol. 43, no. 6, pp. 2438–2451, 1979. View at Publisher · View at Google Scholar
  22. J. H. Goldie, A. J. Coldman, and G. A. Gudauskas, “Rationale for the use of alternating non-cross-resistant chemotherapy,” Cancer Treatment Reports, vol. 66, pp. 439–449, 1982. View at Google Scholar
  23. J. Cortes, D. Thomas, A. Rios et al., “Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia,” Cancer, vol. 94, no. 5, pp. 1492–1499, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. L. Brunetto, L. A. Castillo, A. S. Petrilli et al., “Carboplatin in the treatment of Ewing sarcoma: results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1,” Pediatric Blood & Cancer, vol. 62, no. 10, pp. 1747–1753, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Van Winkle, A. Angiolillo, M. Krailo et al., “Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience,” Pediatric Blood & Cancer, vol. 44, no. 4, pp. 338–347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. van Maldegem, C. Benson, P. Rutkowski et al., “Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study,” Pediatric Blood & Cancer, vol. 62, no. 1, pp. 40–44, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. A. El Weshi, M. Memon, M. Raja et al., “VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors,” American Journal of Clinical Oncology, vol. 27, no. 5, pp. 529–534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J. I. Albergo, C. L. Gaston, M. Laitinen et al., “Ewing’s sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response,” Bone & Joint Journal, vol. 98-B, no. 8, pp. 1138–1144, 2016. View at Publisher · View at Google Scholar